Switch theme
Sign up to access all valuation multiples
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
2000
1.8K+
LTM Revenue $677M
LTM EBITDA -$24.3M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HUTCHMED has a last 12-month revenue (LTM) of $677M and a last 12-month EBITDA of -$24.3M.
In the most recent fiscal year, HUTCHMED achieved revenue of $846M and an EBITDA of $18.9M.
HUTCHMED expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HUTCHMED valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $677M | XXX | $846M | XXX | XXX | XXX |
| Gross Profit | $312M | XXX | $378M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | -$24.3M | XXX | $18.9M | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | 2% | XXX | XXX | XXX |
| EBIT | -$34.0M | XXX | -$54.5M | XXX | XXX | XXX |
| EBIT Margin | -5% | XXX | -6% | XXX | XXX | XXX |
| Net Profit | $175M | XXX | $50.7M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, HUTCHMED's stock price is GBP 2 (or $3).
HUTCHMED has current market cap of GBP 1.8B (or $2.4B), and EV of GBP 1.2B (or $1.6B).
See HUTCHMED trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $2.4B | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, HUTCHMED has market cap of $2.4B and EV of $1.6B.
HUTCHMED's trades at 1.9x EV/Revenue multiple, and 85.4x EV/EBITDA.
Equity research analysts estimate HUTCHMED's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HUTCHMED has a P/E ratio of 13.5x.
See valuation multiples for HUTCHMED and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | -66.5x | XXX | 85.4x | XXX | XXX | XXX |
| EV/EBIT | -47.6x | XXX | -29.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.5x | XXX | 46.7x | XXX | XXX | XXX |
| EV/FCF | 10.5x | XXX | -69.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHUTCHMED's last 12 month revenue growth is 14%
HUTCHMED's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
HUTCHMED's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HUTCHMED's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HUTCHMED and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | -131% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HUTCHMED acquired XXX companies to date.
Last acquisition by HUTCHMED was XXXXXXXX, XXXXX XXXXX XXXXXX . HUTCHMED acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was HUTCHMED founded? | HUTCHMED was founded in 2000. |
| Where is HUTCHMED headquartered? | HUTCHMED is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does HUTCHMED have? | As of today, HUTCHMED has 1.8K+ employees. |
| Who is the CEO of HUTCHMED? | HUTCHMED's CEO is Dr. Weiguo Su. |
| Is HUTCHMED publicy listed? | Yes, HUTCHMED is a public company listed on LON. |
| What is the stock symbol of HUTCHMED? | HUTCHMED trades under HCM ticker. |
| When did HUTCHMED go public? | HUTCHMED went public in 2006. |
| Who are competitors of HUTCHMED? | Similar companies to HUTCHMED include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of HUTCHMED? | HUTCHMED's current market cap is $2.4B |
| What is the current revenue of HUTCHMED? | HUTCHMED's last 12 months revenue is $677M. |
| What is the current revenue growth of HUTCHMED? | HUTCHMED revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of HUTCHMED? | Current revenue multiple of HUTCHMED is 2.4x. |
| Is HUTCHMED profitable? | Yes, HUTCHMED is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of HUTCHMED? | HUTCHMED's last 12 months EBITDA is -$24.3M. |
| What is HUTCHMED's EBITDA margin? | HUTCHMED's last 12 months EBITDA margin is -4%. |
| What is the current EV/EBITDA multiple of HUTCHMED? | Current EBITDA multiple of HUTCHMED is -66.5x. |
| What is the current FCF of HUTCHMED? | HUTCHMED's last 12 months FCF is $153M. |
| What is HUTCHMED's FCF margin? | HUTCHMED's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of HUTCHMED? | Current FCF multiple of HUTCHMED is 10.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
